Analysts Set Haemonetics Corporation (NYSE:HAE) Target Price at $96.80

Haemonetics Corporation (NYSE:HAE - Get Free Report) has earned an average recommendation of "Buy" from the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $97.30.

Several equities analysts have weighed in on the company. Baird R W raised Haemonetics to a "strong-buy" rating in a research report on Wednesday, June 25th. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Needham & Company LLC dropped their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Raymond James Financial reissued a "strong-buy" rating and set a $105.00 price target (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, JMP Securities reissued a "market outperform" rating and set a $100.00 price target on shares of Haemonetics in a research report on Tuesday, May 20th.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently made changes to their positions in HAE. TD Waterhouse Canada Inc. acquired a new stake in shares of Haemonetics during the fourth quarter worth $25,000. Quarry LP boosted its holdings in shares of Haemonetics by 63.4% during the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after purchasing an additional 192 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. acquired a new stake in shares of Haemonetics during the fourth quarter worth $62,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Haemonetics during the first quarter worth $65,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Price Performance

NYSE HAE traded up $1.54 during mid-day trading on Wednesday, hitting $79.06. The stock had a trading volume of 110,748 shares, compared to its average volume of 671,280. Haemonetics has a 52-week low of $55.30 and a 52-week high of $94.99. The company has a market cap of $3.80 billion, a price-to-earnings ratio of 23.96, a P/E/G ratio of 1.23 and a beta of 0.39. The company has a 50 day simple moving average of $70.20 and a 200 day simple moving average of $68.05. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period last year, the business posted $0.90 EPS. Haemonetics's quarterly revenue was down 3.5% on a year-over-year basis. Equities analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.